Our mission

Elkedonia is committed to introducing a pioneering, first-in-class antidepressant treatment with precision medicine.


Our ambition is to develop an innovative antidepressant treatment, that will be accessible to all patients, whatever their geographical location, age or comorbidities, fast-acting and free from risks of dependence, sedation or psychotic effects.

Our goal is to enable patients to rediscover the pleasures of life and significantly reduce the risks of suicide and relapse.

Scientist using a microscope

Our history

2000 Role of Elk-1 in
memory described by the research of Dr Jocelyne Caboche 2011 Anti-addictive effects
of Elk-1 inhibition in preclinical studies 2011 Effects of Elk-1 inhibition
on neuroplasticity demonstrated in preclinical studies 2018 Clinical evidence that
Elk-1 could act as
a therapeutic lever in Major Depressive Disorders 2022 Launch of a preincubation
program at Argobio Studio 2023 Superiority over classical
antidepressants demonstrated in preclinical studies 2025 Launch of Elkedonia

This is Elkedonia

Elkedonia is focused on developing a safe, well-tolerated and effective therapy for depression, ensuring it is accessible to every patient in need.

Innovative
We are pioneers

Elkedonia is leading a pioneering approach in antidepressant therapy. We are focusing on an innovative target, within neurons, in key brain circuits. Rather than acting at the synapse like all other antidepressants, our approach targets intracellular events and neuroplasticity, precisely targeting a highly selective signaling pathway.

Committed
A team of dedicated and unique people

Our values – Innovation, Commitment, Ambition and REsilience – come together to form our credo: ‘I CARE’, reflecting our desire to make a significant difference in patients’ lives.

Ambitious
Redefining relief with a breakthrough antidepressant for all patients

Evidence from both patient studies and preclinical research supports the role of our target in depression pathophysiology. Inhibiting its activity is expected to provide rapid and long-lasting relief for all patients. Our ambition is to act on key brain circuits to rewire resilience and bring patients new levels of relief.

Resilient
Learning and adapting to move forward

We see beyond challenges, identifying ways to turn them into opportunities. This approach is key in R&D for complex disorders, like mental health disorders. Driven by our passion to contribute to the bigger picture, we keep an open mind to advance innovation.

Meet our team

We believe that great breakthroughs are born from the collaboration of passionate minds. Together, we transform biotechnological innovations into tangible solutions for tomorrow.

Contact us for more details
Team Board of Directors Scientific Advisory Board

They already support us